Investor Presentation - First Six Months of 2021

9 Investor presentation First six months of 2021 In the last 12 months, Novo Nordisk increased market share in the fast-growing US GLP-1 segment NBRX share 80% US GLP-1 NBRx market share US GLP-1 TRX market share TRX share Class growth ~25% 60% 48.7% 56.5% 60% 40% 20% 0% July 2020 Ozempic 62.6% 40% 41.7% 35.4% 20% 12.9% Novo Nordisk® 51.3% 45.0% 31.0% 14.1% 6.3% 7.9% 0% July 2021 July 2020 July 2021 RybelsusⓇ VictozaⓇ NN GLP-1 QD dulaglutide Source: IQVIA Xponent, Weekly (ending 16 July 2021) Each data points represents a rolling four-week average NBRX: New-to-brand prescriptions; TRx: Total prescriptions; NN: Novo Nordisk Note: Class growth calculated as Q2 2020 vs Q2 2021

View entire presentation